International Edition
World Markets FX Policy

Monday, 5 October 2026

Private Trade News

Global markets, trading & world business — for professional traders

Markets

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Private Trade News venue-risk note (2026-10-04): Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC… Primary source: original at Nasdaq (nasdaq.com).

· Nasdaq

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Dr

Read at source

Read also